251 related articles for article (PubMed ID: 21459712)
1. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in breast cancer: BRCA and beyond.
Rios J; Puhalla S
Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
[TBL] [Abstract][Full Text] [Related]
7. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
Mangerich A; Bürkle A
Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
[TBL] [Abstract][Full Text] [Related]
8. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
11. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
12. [Poly(ADP-ribose) polymerase-1 as a regulator of protein-nucleic acid interactions in the processes responding to genotoxic action].
Sukhanova MV; Lavrik OI; Khodyreva SN
Mol Biol (Mosk); 2004; 38(5):834-47. PubMed ID: 15554186
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
Plummer R
Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
15. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
16. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
Makogon NV; Aleksieieva IM
Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
[TBL] [Abstract][Full Text] [Related]
17. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
Helleday T
Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104
[TBL] [Abstract][Full Text] [Related]
18. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Tentori L; Portarena I; Graziani G
Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
[TBL] [Abstract][Full Text] [Related]
19. Discussion of PARP inhibitors in cancer therapy.
Wielgos M; Yang ES
Pharm Pat Anal; 2013 Nov; 2(6):755-66. PubMed ID: 24237241
[TBL] [Abstract][Full Text] [Related]
20. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
Li M; Yu X
Oncogene; 2015 Jun; 34(26):3349-56. PubMed ID: 25220415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
